Nathalie Asherie

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Nico Gagelmann, Danai Dima, Maximilian Merz et al. · Journal of Clinical Oncology · 2024 · 70 citations · Full text

Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

Shlomit Kfir‐Erenfeld, Nathalie Asherie, Sigal Grisariu et al. · Clinical Cancer Research · 2022 · 36 citations

Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial

Nathalie Asherie, Shlomit Kfir‐Erenfeld, Batia Avni et al. · Haematologica · 2022 · 26 citations · Full text

Hematological Malignancy, Car T Cells, Radiation Oncology +14

Early lymphocyte collection for <scp>anti‐CD19 CART</scp> production improves T‐cell fitness in patients with relapsed/refractory diffuse large B‐cell lymphoma

Tatyana Dubnikov Sharon, Miri Assayag, Batia Avni et al. · British Journal of Haematology · 2023 · 20 citations · Full text

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma

Ortal Harush, Nathalie Asherie, Shlomit Kfir‐Erenfeld et al. · Haematologica · 2022 · 18 citations · Full text

Car Primary Structure, Immunology, Structural Optimization +16